Digistain – Health Tech Challengers 2023 Finalist
October 12, 2023
Digistain works with CORE Diagnostics (India)
September 4, 2024
London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was published in Breast Cancer Research and Treatment. The study reports the prognostic performance of the Digistain Prognostic Score; please see the publication for full results.
